SYRACUSE, N.Y.--(BUSINESS WIRE)--Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough ...

Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study PURPOSE: To ...

Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture. ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit ...

March 12, 2009 (San Diego, California) — For patients with painful bone metastases and benign lytic lesions that do not respond to conventional analgesic therapy, percutaneous osteoplasty might be an ...

Allogeneic SCT for myeloma may be curative for young patients, but its role remains controversial because of a reported high TRM in some series. Since 1991, we have performed 25 allografts for myeloma ...

A study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful ...

Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic and primary breast cancers, ...